New Fingernail Psoriasis Clinical Outcome Measure is Valid, Reliable
Researchers assessed the validity and reliability of the Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) in the treatment of patients with psoriatic arthritis.
Spondyloarthritis
Standardized Definition Needed for Early Spondyloarthritis
Researchers sought to identify all possible definitions of early spondyloarthritis, including early axial spondyloarthritis and early peripheral spondyloarthritis.
Psoriasis Impacts Characteristics, Treatment of Peripheral Spondyloarthritis
Researchers evaluated the clinical characteristics, disease burden, and treatment of patients with peripheral spondyloarthritis with and without psoriasis.
Site of Infection Associated With Increased Risk for PsA and Psoriasis
Researchers evaluated the association between pharyngeal infections and incident psoriatic arthritis and psoriasis.
High Erythrocyte Mean Corpuscular Volume Predicts Methotrexate Response in PsA
Researchers investigated the generalizability of a previous study finding that increased mean corpuscular volume complements clinical response in psoriatic arthritis.
![There are no uniform guidelines regarding DMARD tapering. EULAR guidelines suggest RA pharmacotherapy should be de-escalated in the following order: glucocorticoids, biologic DMARDs, and, finally, conventional DMARDs, with each treatment stopping completely before de-escalation of the next agent in the sequence.[4] Numerous DMARD dose-tapering protocols have been studied, including immediate discontinuation of treatment. When the goal is to withdraw treatment, the ACR recommends an initial dose-tapering phase to enable better monitoring of patient response and candidacy for discontinuation.[5] The ACR also strongly encourages patient involvement in decisions regarding their individual DMARD tapering protocol.](https://www.dermatologyadvisor.com/wp-content/uploads/sites/20/2022/04/syringedrugsts53728911801_1026507-544x306.jpg)
Comparing the Efficacy, Safety of Systemic Therapies in the Treatment of PsA Manifestations
Authors of a systematic review compared the efficacy and safety of systemic therapies in the treatment of manifestations of active psoriatic arthritis.
Risk for Severe COVID-19 Low in Patients With Psoriatic Disease
Researchers reported on the severity of COVID-19 outcomes in patients with psoriatic disease, using data from the WARCOV study.
Increased Risk for Venous Thromboembolism Events in Patients With PsA Linked to Underlying Comorbidities
The objective of the study was to assess the association between psoriatic arthritis and venous thromboembolism events.
Transition From Onset of Psoriasis to Psoriatic Arthritis Linked to Distinct Clinical Phenotypes
Researchers assessed the demographic and clinical characteristics associated with transition time between psoriasis and psoriatic arthritis.
Guselkumab Improves PsA in Patients With Inadequate Response to TNFi
The phase 3 COSMOS study evaluated the efficacy and safety of guselkumab in 285 adults with active PsA who had an inadequate response to anti-tumor necrosis factors.
- Loading...
Loading...
Next post in Psoriasis
Loading... 
Loading...